CytoMed Therapeutics Limited (GDTC)
(Delayed Data from NSDQ)
$1.86 USD
+0.02 (1.09%)
Updated Aug 7, 2025 11:44 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Market Cap
As of the previous market close, CytoMed Therapeutics Limited has a market cap of $26.20M, which represents its share price of $2.40 multiplied by its outstanding shares number of 10.94M. As a small-cap company, GDTC's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
GDTC 1.86 +0.02(1.09%)
Will GDTC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GDTC based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for GDTC
12 Health Care Stocks Moving In Wednesday's Intraday Session
GDTC Completes Initial Phase in Cancer Clinical Trial | GDTC Stock News
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 ...
Cytomed Therapeutics completes dose level 1 of ANGELICA trial
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shelf Offering | GDTC Stock News